• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 MCMV 的疫苗载体表达全长病毒蛋白,单次接种即可提供长期体液免疫保护。

MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination.

机构信息

Department of Viral Immunology, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany.

Department of Biotechnology, Institut für Biochemie, Biotechnologie und Bioinformatik, Technischen Universität Braunschweig, Braunschweig, Germany.

出版信息

Cell Mol Immunol. 2022 Feb;19(2):234-244. doi: 10.1038/s41423-021-00814-5. Epub 2022 Jan 7.

DOI:10.1038/s41423-021-00814-5
PMID:34992275
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8739032/
Abstract

Global pandemics caused by influenza or coronaviruses cause severe disruptions to public health and lead to high morbidity and mortality. There remains a medical need for vaccines against these pathogens. CMV (cytomegalovirus) is a β-herpesvirus that induces uniquely robust immune responses in which remarkably large populations of antigen-specific CD8 T cells are maintained for a lifetime. Hence, CMV has been proposed and investigated as a novel vaccine vector for expressing antigenic peptides or proteins to elicit protective cellular immune responses against numerous pathogens. We generated two recombinant murine CMV (MCMV) vaccine vectors expressing hemagglutinin (HA) of influenza A virus (MCMV) or the spike protein of severe acute respiratory syndrome coronavirus 2 (MCMV). A single injection of MCMVs expressing either viral protein induced potent neutralizing antibody responses, which strengthened over time. Importantly, MCMV-vaccinated mice were protected from illness following challenge with the influenza virus, and we excluded that this protection was due to the effects of memory T cells. Conclusively, we show here that MCMV vectors induce not only long-term cellular immunity but also humoral responses that provide long-term immune protection against clinically relevant respiratory pathogens.

摘要

由流感病毒或冠状病毒引起的全球大流行严重扰乱了公共卫生,导致高发病率和死亡率。人们仍然需要针对这些病原体的疫苗。CMV(巨细胞病毒)是一种β疱疹病毒,它诱导出独特的强大免疫反应,在这种反应中,大量的抗原特异性 CD8 T 细胞被终生维持。因此,CMV 已被提议并研究作为一种新型疫苗载体,用于表达抗原肽或蛋白,以引发针对多种病原体的保护性细胞免疫反应。我们生成了两种表达甲型流感病毒血凝素(HA)(MCMV)或严重急性呼吸综合征冠状病毒 2 刺突蛋白(MCMV)的重组鼠 CMV(MCMV)疫苗载体。单次注射表达任何一种病毒蛋白的 MCMV 均可诱导强烈的中和抗体反应,且随着时间的推移而增强。重要的是,MCMV 疫苗接种的小鼠在感染流感病毒后免受疾病的侵害,我们排除了这种保护作用是由于记忆 T 细胞的作用。总之,我们在这里表明,MCMV 载体不仅诱导长期的细胞免疫,而且还诱导体液免疫反应,为临床相关呼吸道病原体提供长期的免疫保护。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92c7/8803854/295414ddfc25/41423_2021_814_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92c7/8803854/543a2bc24b56/41423_2021_814_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92c7/8803854/fe0f8f196a5f/41423_2021_814_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92c7/8803854/0532f1bb9f85/41423_2021_814_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92c7/8803854/295414ddfc25/41423_2021_814_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92c7/8803854/543a2bc24b56/41423_2021_814_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92c7/8803854/fe0f8f196a5f/41423_2021_814_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92c7/8803854/0532f1bb9f85/41423_2021_814_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92c7/8803854/295414ddfc25/41423_2021_814_Fig4_HTML.jpg

相似文献

1
MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination.基于 MCMV 的疫苗载体表达全长病毒蛋白,单次接种即可提供长期体液免疫保护。
Cell Mol Immunol. 2022 Feb;19(2):234-244. doi: 10.1038/s41423-021-00814-5. Epub 2022 Jan 7.
2
A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variants.一种单次剂量的基于 MCMV 的疫苗可在小鼠中引发针对不同 SARS-CoV-2 变体的持久免疫保护。
Front Immunol. 2024 Jul 25;15:1383086. doi: 10.3389/fimmu.2024.1383086. eCollection 2024.
3
Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.口腔细菌与鼻腔疫苗联合使用可预防甲型流感病毒和 SARS-CoV-2 感染。
mBio. 2021 Aug 31;12(4):e0159821. doi: 10.1128/mBio.01598-21. Epub 2021 Aug 17.
4
A decavalent composite mRNA vaccine against both influenza and COVID-19.一种针对流感和 COVID-19 的十价复合 mRNA 疫苗。
mBio. 2024 Sep 11;15(9):e0066824. doi: 10.1128/mbio.00668-24. Epub 2024 Aug 6.
5
A chimeric mRNA vaccine of S-RBD with HA conferring broad protection against influenza and COVID-19 variants.一种含有 S-RBD 和 HA 的嵌合 mRNA 疫苗,可提供针对流感和 COVID-19 变体的广泛保护。
PLoS Pathog. 2024 Sep 20;20(9):e1012508. doi: 10.1371/journal.ppat.1012508. eCollection 2024 Sep.
6
Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice.鼻腔内接种 SARS-CoV-2 奥密克戎变异株疫苗可在雌性小鼠中诱导体液和细胞黏膜免疫。
EBioMedicine. 2024 Jul;105:105185. doi: 10.1016/j.ebiom.2024.105185. Epub 2024 Jun 7.
7
A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.一种用于诱导重组 SARS-CoV-2 蛋白疫苗产生有效抗病毒免疫应答的联合佐剂。
Front Immunol. 2021 Sep 16;12:729189. doi: 10.3389/fimmu.2021.729189. eCollection 2021.
8
A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.一种二价异源DNA病毒样颗粒初免-加强疫苗可引发针对1型和2型甲型流感病毒的广泛保护。
J Virol. 2017 Apr 13;91(9). doi: 10.1128/JVI.02052-16. Print 2017 May 1.
9
Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity.辛德毕斯-严重急性呼吸综合征冠状病毒 2 刺突疫苗与 αOX40 抗体联合使用可针对严重急性呼吸综合征冠状病毒 2 诱导的疾病产生保护免疫,并增强长期的严重急性呼吸综合征冠状病毒 2 特异性体液和 T 细胞免疫。
Front Immunol. 2021 Jul 29;12:719077. doi: 10.3389/fimmu.2021.719077. eCollection 2021.
10
Non-neutralizing SARS CoV-2 directed polyclonal antibodies demonstrate cross-reactivity with the HA glycans of influenza virus.非中和性 SARS-CoV-2 定向多克隆抗体显示与流感病毒 HA 糖基具有交叉反应性。
Int Immunopharmacol. 2021 Oct;99:108020. doi: 10.1016/j.intimp.2021.108020. Epub 2021 Jul 29.

引用本文的文献

1
Can Humanized Immune System Mouse and Rat Models Accelerate the Development of Cytomegalovirus-Based Vaccines Against Infectious Diseases and Cancers?人源化免疫系统小鼠和大鼠模型能否加速基于巨细胞病毒的抗传染病和癌症疫苗的研发?
Int J Mol Sci. 2025 Mar 27;26(7):3082. doi: 10.3390/ijms26073082.
2
Heightened innate immune state induced by viral vector leads to enhanced response to challenge and prolongs malaria vaccine protection.病毒载体诱导的先天免疫状态增强可导致对攻击的反应增强,并延长疟疾疫苗的保护作用。
iScience. 2024 Nov 26;27(12):111468. doi: 10.1016/j.isci.2024.111468. eCollection 2024 Dec 20.
3
Recombinant Hemagglutinin Protein from H9N2 Avian Influenza Virus Exerts Good Immune Effects in Mice.

本文引用的文献

1
Construction of Human Cytomegalovirus Mutants with Markerless BAC Mutagenesis.构建无标记 BAC 诱变的人巨细胞病毒突变体。
Methods Mol Biol. 2021;2244:133-158. doi: 10.1007/978-1-0716-1111-1_8.
2
mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2.mRNA 诱导的人血管紧张素转换酶 2 在小鼠中的表达,用于研究对严重急性呼吸综合征冠状病毒 2 的适应性免疫反应。
PLoS Pathog. 2020 Dec 16;16(12):e1009163. doi: 10.1371/journal.ppat.1009163. eCollection 2020 Dec.
3
Covid-19: UK approves Pfizer and BioNTech vaccine with rollout due to start next week.
H9N2禽流感病毒重组血凝素蛋白对小鼠具有良好的免疫效果。
Microorganisms. 2024 Jul 29;12(8):1552. doi: 10.3390/microorganisms12081552.
4
A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variants.一种单次剂量的基于 MCMV 的疫苗可在小鼠中引发针对不同 SARS-CoV-2 变体的持久免疫保护。
Front Immunol. 2024 Jul 25;15:1383086. doi: 10.3389/fimmu.2024.1383086. eCollection 2024.
5
Cytomegalovirus vaccine vector-induced effector memory CD4 + T cells protect cynomolgus macaques from lethal aerosolized heterologous avian influenza challenge.巨细胞病毒疫苗载体诱导的效应记忆 CD4+T 细胞保护食蟹猴免受致死性雾化异源禽流感挑战。
Nat Commun. 2024 Jul 19;15(1):6007. doi: 10.1038/s41467-024-50345-6.
6
Very Broadly Effective Hemagglutinin-Directed Influenza Vaccines with Anti-Herpetic Activity.具有抗疱疹活性的广谱高效血凝素导向流感疫苗。
Vaccines (Basel). 2024 May 14;12(5):537. doi: 10.3390/vaccines12050537.
7
Vero cell-adapted SARS-CoV-2 strain shows increased viral growth through furin-mediated efficient spike cleavage.通过弗林蛋白酶介导的高效刺突裂解,适应vero 细胞的 SARS-CoV-2 毒株显示出增强的病毒生长。
Microbiol Spectr. 2024 Apr 2;12(4):e0285923. doi: 10.1128/spectrum.02859-23. Epub 2024 Feb 28.
8
The Quest for Immunity: Exploring Human Herpesviruses as Vaccine Vectors.追求免疫:探索人类疱疹病毒作为疫苗载体。
Int J Mol Sci. 2023 Nov 9;24(22):16112. doi: 10.3390/ijms242216112.
9
Cytomegalovirus-vectored COVID-19 vaccines elicit neutralizing antibodies against the SARS-CoV-2 Omicron variant (BA.2) in mice.基于细胞的巨细胞病毒 COVID-19 疫苗在小鼠中诱导针对 SARS-CoV-2 奥密克戎变异株(BA.2)的中和抗体。
Microbiol Spectr. 2023 Dec 12;11(6):e0246323. doi: 10.1128/spectrum.02463-23. Epub 2023 Nov 16.
10
Exploring the Potential of Cytomegalovirus-Based Vectors: A Review.探索巨细胞病毒载体的潜力:综述。
Viruses. 2023 Oct 2;15(10):2043. doi: 10.3390/v15102043.
新冠疫情:英国批准辉瑞和生物科技公司的疫苗,下周开始推广接种。
BMJ. 2020 Dec 2;371:m4714. doi: 10.1136/bmj.m4714.
4
COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses.COVID-19 疫苗 BNT162b1 可引发人体抗体和 T1 T 细胞应答。
Nature. 2020 Oct;586(7830):594-599. doi: 10.1038/s41586-020-2814-7. Epub 2020 Sep 30.
5
Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor.糖基化 SARS-CoV-2 刺突蛋白与人血管紧张素转换酶 2 受体的病毒-受体相互作用。
Cell Host Microbe. 2020 Oct 7;28(4):586-601.e6. doi: 10.1016/j.chom.2020.08.004. Epub 2020 Aug 24.
6
A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells.SARS-CoV-2 刺突蛋白中的多碱性裂解位点对于感染人肺细胞至关重要。
Mol Cell. 2020 May 21;78(4):779-784.e5. doi: 10.1016/j.molcel.2020.04.022. Epub 2020 May 1.
7
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.一种用于中东呼吸综合征的改良安卡拉痘苗病毒载体候选疫苗的安全性和免疫原性:一项开放性、1 期临床试验。
Lancet Infect Dis. 2020 Jul;20(7):827-838. doi: 10.1016/S1473-3099(20)30248-6. Epub 2020 Apr 21.
8
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)进入细胞依赖于 ACE2 和 TMPRSS2,可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
9
Interim Estimates of 2019-20 Seasonal Influenza Vaccine Effectiveness - United States, February 2020.2019-20 季节性流感疫苗效力的临时估计-美国,2020 年 2 月。
MMWR Morb Mortal Wkly Rep. 2020 Feb 21;69(7):177-182. doi: 10.15585/mmwr.mm6907a1.
10
Immunization with a murine cytomegalovirus based vector encoding retrovirus envelope confers strong protection from Friend retrovirus challenge infection.用编码逆转录病毒包膜的鼠巨细胞病毒载体免疫可强烈保护免受 Friend 逆转录病毒攻击感染。
PLoS Pathog. 2019 Sep 30;15(9):e1008043. doi: 10.1371/journal.ppat.1008043. eCollection 2019 Sep.